MP26-05 PREVALENCE OF CLINICALLY APPARENT PROLACTINOMAS IN THE SUBFERTILE MALE

Abstract

You have accessJournal of UrologyInfertility: Epidemiology & Evaluation I (MP26)1 Apr 2020MP26-05 PREVALENCE OF CLINICALLY APPARENT PROLACTINOMAS IN THE SUBFERTILE MALE Anne Darves-Bornoz*, Mehul Patel, Mary Kate Keeter, James Wren, Nelson Bennett, Joshua Halpern, and Robert Brannigan Anne Darves-Bornoz*Anne Darves-Bornoz* More articles by this author , Mehul PatelMehul Patel More articles by this author , Mary Kate KeeterMary Kate Keeter More articles by this author , James WrenJames Wren More articles by this author , Nelson BennettNelson Bennett More articles by this author , Joshua HalpernJoshua Halpern More articles by this author , and Robert BranniganRobert Brannigan More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000865.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The physiologic role of prolactin in men remains unclear. However, excessive serum concentrations of prolactin can lead to clinical sequelae such as infertility and hypogonadism. Using population-based studies, the prevalence of prolactinoma in the general male population is estimated at 1:100,000 (0.0001%). Although a well-established cause of male infertility, the prevalence of prolactinoma within this subgroup has not been evaluated. METHODS: We retrospectively examined all men presenting for initial male fertility consultation at a tertiary care center with a single reproductive urologist between 1999 and 2018. Men with a prolactin level collected at this encounter were analyzed with descriptive statistics to determine incidence of hyperprolactinemia and resulting clinical significance. RESULTS: Among 4116 men presenting for initial fertility consultation, 3102 had a serum prolactin level measured. 65 men (2.1%) had a prolactin level greater than or equal to 18 ng/mL. Of the 65 men with an initial elevated prolactin level, 21 (32.3%) were evaluated by an endocrinologist and 21 (32.3%) underwent a brain MRI. 11/65 (17%) were diagnosed with a pituitary adenoma, of which 8 were microadenomas (<10 mm on MRI) and 3 were macroadenomas (>10mm). 8 of the 11 men with a prolactinoma were treated with cabergoline. The overall prevalence of a clinically apparent prolactinoma in our cohort was 11:3102 (0.35%). CONCLUSIONS: This is the largest known study to evaluate the prevalence of prolactinomas among a population of subfertile males. We found a 350-fold increased prevalence of prolactinoma among our cohort when compared to the general male population. Despite a low absolute prevalence, prolactinoma remains an important source of morbidity and potential etiology for subfertility, and clinicians should continue to include this condition in the differential diagnosis of male subfertility. Source of Funding: None © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e401-e402 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Anne Darves-Bornoz* More articles by this author Mehul Patel More articles by this author Mary Kate Keeter More articles by this author James Wren More articles by this author Nelson Bennett More articles by this author Joshua Halpern More articles by this author Robert Brannigan More articles by this author Expand All Advertisement PDF downloadLoading ...